ABPI responds to CDF's drug re-evaluation process

The Association of the British Pharmaceutical Industry (ABPI) said it is "disappointed" by a newly released (see BioCentury Extra, Aug. 28).

In its "Standard Operating Procedures: The Cancer Drugs Fund 2013-14," CDF said it will remove coverage of the least effective cancer drugs. CDF's method for prioritizing drugs includes adding the median drug cost per patient to an aggregated clinical impact score, which includes assessments of PFS, OS, quality of life, toxicity and unmet need. The cutoff for removal of coverage will be based on CDF's budget. ...